Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose Escalation and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of BND-35 Administered Alone and in Combination With Nivolumab or With Cetuximab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, Dose Escalation and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of BND-35 Administered Alone and in Combination With Nivolumab or With Cetuximab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BND 35 (Primary) ; Cetuximab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Biond Biologics

Most Recent Events

  • 24 Jun 2024 According to a Biond Biologics media release, the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody.
  • 24 Jun 2024 Status changed from not yet recruiting to recruiting, according to a Biond Biologics media release.
  • 26 Mar 2024 According to an Biond Biologics media release, the company has received IND clearance for BND-35, this trial is expected to start in April, 2024. The trial design of this study will be presented at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 5 - 10, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top